Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Valion Bio, Inc.TIVC · Entity 8459 | Director · Chief Executive Officer | December 18, 2025 | December 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Valion Bio, Inc.
Report date December 18, 2025 · Filed December 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,691 |
Ending reported balance
After 2025-12-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-18 · Exercise / conversion · Acquired 14,706 · Balance 37,953 F1: Each Restricted Stock Unit is convertible into one share of Common Stock. Row 2 · 2025-12-18 · Tax withholding · Disposed 5,262 · Balance 32,691 F2: The Reporting Person forfeited 5,262 shares of Common Stock upon vesting and settlement of 14,706 outstanding Restricted Stock Units to cover tax withholdings, using the market price of the Issuer's common stock at the time of forfeiture. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,706 |
Reported balance
After 2025-12-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-18 · Exercise / conversion · Disposed 14,706 · Balance 14,706 F1: Each Restricted Stock Unit is convertible into one share of Common Stock. F3: Fifty percent (50%) of the Restricted Stock Units will vest upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit is convertible into one share of Common Stock.
F2: The Reporting Person forfeited 5,262 shares of Common Stock upon vesting and settlement of 14,706 outstanding Restricted Stock Units to cover tax withholdings, using the market price of the Issuer's common stock at the time of forfeiture.
F3: Fifty percent (50%) of the Restricted Stock Units will vest upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2025 Filed Dec 22, 2025 20:44 UTC | Valion Bio, Inc. TIVC · Entity 8459 | Exercise / conversionRestricted Stock Units · Derivative | 14,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-009305 · ownership.xml · derivative · entry 3 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,706 Underlying: Common Stock · 14,706 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit is convertible into one share of Common Stock. F3 · derivative.exercise_date: Fifty percent (50%) of the Restricted Stock Units will vest upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: Fifty percent (50%) of the Restricted Stock Units will vest upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. Read SEC document |
| December 18, 2025 Filed Dec 22, 2025 20:44 UTC | Valion Bio, Inc. TIVC · Entity 8459 | Tax withholdingCommon Stock | 5,262 | $1.87 | $9,839.94 |
DisclosureSEC source: 0001683168-25-009305 · ownership.xml · nonDerivative · entry 2 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,691 F2 · kind: The Reporting Person forfeited 5,262 shares of Common Stock upon vesting and settlement of 14,706 outstanding Restricted Stock Units to cover tax withholdings, using the market price of the Issuer's common stock at the time of forfeiture. Read SEC document |
| December 18, 2025 Filed Dec 22, 2025 20:44 UTC | Valion Bio, Inc. TIVC · Entity 8459 | Exercise / conversionCommon Stock | 14,706 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-25-009305 · ownership.xml · nonDerivative · entry 1 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit is convertible into one share of Common Stock. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:02 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantCommon Stock | 22,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-007223 · ownership.xml · nonDerivative · entry 1 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,247 Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 18:45 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Purchase) · Derivative | 85,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001683168-25-005833 · ownership.xml · derivative · entry 1 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2035-08-05 F1 · derivative.exercise_date: The stock option vests as follows: (i) 50% upon the first anniversary of the grant date, and (ii) the remaining 50% in a series of twelve (12) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the first anniversary of the grant date, such that 100% of the stock option will be vested upon the fourth anniversary of the grant date. Read SEC document |
| August 06, 2025 Filed Aug 22, 2025 20:00 UTC Amendment | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Purchase) · Derivative | 85,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001683168-25-006428 · ownership.xml · derivative · entry 1 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2035-08-05 F1 · derivative.exercise_date: This Amendment No. 1 ("Form 4/A") to the Form 4 filed by the reporting person on August 8, 2025 (the "Original Form 4") is being filed to correct an administrative error, resulting in the incorrect vesting schedule for the stock option being included in the Original Form 4. As reflected in this Form 4/A, the stock option vests as follows: (i) 25% upon the first anniversary of the grant date, and (ii) the remaining 75% in a series of twelve (12) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the first anniversary of the grant date, such that 100% of the stock option will be vested upon the fourth anniversary of the grant date. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 17:15 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantRestricted Stock Units · Derivative | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-008900 · ownership.xml · derivative · entry 1 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-12-17 F1 · derivative.exercise_price: Each Restricted Stock Unit is convertible into one share of Common Stock. F2 · derivative.exercise_date: Fifty percent (50%) of the Restricted Stock Units will vest upon the one (1) year anniversary of the Vesting Commencement Date, and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. Read SEC document |
| March 12, 2024 Filed Mar 22, 2024 18:47 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0000950170-24-035553 · ownership.xml · derivative · entry 1 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2034-03-11 F1 · derivative.exercise_date: The option vests as follows: (i) 50% on the first anniversary of the grant date and (ii) the remaining 50% in 12 equal monthly installments over the 12 months thereafter. Read SEC document |
| May 08, 2023 Filed May 10, 2023 18:46 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0000899243-23-012535 · doc4.xml · derivative · entry 1 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-07 F1 · derivative.exercise_date: The option vests as follows: (i) 25% one year from the grant date, and (ii) the remaining 75% in equal monthly installments over the 36 months thereafter. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 17:34 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001104659-22-014166 · tm225821d2_4.xml · derivative · entry 1 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-02-03 F1 · derivative.exercise_date: The option vests as follows: (i) 25% one year from the grant date, and (ii) the remaining 75% in equal monthly installments over the next 36 months. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 21:11 UTC | Valion Bio, Inc. TIVC · Entity 8459 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $0.00 Strike: $3.75 | $101,200.00 |
DisclosureSEC source: 0001104659-21-139507 · tm2133057-1_4seq1.xml · derivative · entry 4 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On November 12, 2021, in connection with the Issuer's IPO, the outstanding principal and accrued but unpaid interest of the Convertible Promissory Note (the "Note"), amounting to $100,000 and $1,200, respectively, automatically converted into an aggregate of 26,986 shares of the Issuer's common stock at a conversion price of $3.75 per share, which conversion price was equal to the IPO price per share of the issuer's common stock, less a 25% discount. F2 · price: On November 12, 2021, in connection with the Issuer's IPO, the outstanding principal and accrued but unpaid interest of the Convertible Promissory Note (the "Note"), amounting to $100,000 and $1,200, respectively, automatically converted into an aggregate of 26,986 shares of the Issuer's common stock at a conversion price of $3.75 per share, which conversion price was equal to the IPO price per share of the issuer's common stock, less a 25% discount. F2 · derivative.exercise_date: On November 12, 2021, in connection with the Issuer's IPO, the outstanding principal and accrued but unpaid interest of the Convertible Promissory Note (the "Note"), amounting to $100,000 and $1,200, respectively, automatically converted into an aggregate of 26,986 shares of the Issuer's common stock at a conversion price of $3.75 per share, which conversion price was equal to the IPO price per share of the issuer's common stock, less a 25% discount. F3 · derivative.expiration_date: The Note was scheduled to mature on June 1, 2023. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 21:11 UTC | Valion Bio, Inc. TIVC · Entity 8459 | ConversionSeries Seed-2 Convertible Preferred Stock · Derivative | 5,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-139507 · tm2133057-1_4seq1.xml · derivative · entry 3 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,391 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares 5,566 shares of Series Seed-2 Convertible Preferred Stock held by the Reporting Person automatically converted into 1,391 shares of the Issuer's common stock on November 12, 2021 in connection with the Issuer's initial public offering (the "IPO"). The Series Seed-2 Convertible Preferred Stock had no expiration date. F1 · price: The shares 5,566 shares of Series Seed-2 Convertible Preferred Stock held by the Reporting Person automatically converted into 1,391 shares of the Issuer's common stock on November 12, 2021 in connection with the Issuer's initial public offering (the "IPO"). The Series Seed-2 Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: The shares 5,566 shares of Series Seed-2 Convertible Preferred Stock held by the Reporting Person automatically converted into 1,391 shares of the Issuer's common stock on November 12, 2021 in connection with the Issuer's initial public offering (the "IPO"). The Series Seed-2 Convertible Preferred Stock had no expiration date. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 21:11 UTC | Valion Bio, Inc. TIVC · Entity 8459 | ConversionCommon Stock | 26,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-139507 · tm2133057-1_4seq1.xml · nonDerivative · entry 2 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,199,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: On November 12, 2021, in connection with the Issuer's IPO, the outstanding principal and accrued but unpaid interest of the Convertible Promissory Note (the "Note"), amounting to $100,000 and $1,200, respectively, automatically converted into an aggregate of 26,986 shares of the Issuer's common stock at a conversion price of $3.75 per share, which conversion price was equal to the IPO price per share of the issuer's common stock, less a 25% discount. F2 · price: On November 12, 2021, in connection with the Issuer's IPO, the outstanding principal and accrued but unpaid interest of the Convertible Promissory Note (the "Note"), amounting to $100,000 and $1,200, respectively, automatically converted into an aggregate of 26,986 shares of the Issuer's common stock at a conversion price of $3.75 per share, which conversion price was equal to the IPO price per share of the issuer's common stock, less a 25% discount. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 21:11 UTC | Valion Bio, Inc. TIVC · Entity 8459 | ConversionCommon Stock | 1,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-139507 · tm2133057-1_4seq1.xml · nonDerivative · entry 1 Ernst Jennifer · CIK 0001889915 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,172,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares 5,566 shares of Series Seed-2 Convertible Preferred Stock held by the Reporting Person automatically converted into 1,391 shares of the Issuer's common stock on November 12, 2021 in connection with the Issuer's initial public offering (the "IPO"). The Series Seed-2 Convertible Preferred Stock had no expiration date. F1 · price: The shares 5,566 shares of Series Seed-2 Convertible Preferred Stock held by the Reporting Person automatically converted into 1,391 shares of the Issuer's common stock on November 12, 2021 in connection with the Issuer's initial public offering (the "IPO"). The Series Seed-2 Convertible Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.